Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
— Aramchol is the most clinically advanced, first-in-class, Stearoyl-CoA desaturase1 (SCD1) oral inhibitor, demonstrating in Ph2 and Ph3 (open label part) an excellent safety profile with metabolic and anti-fibrotic effects. — Galmed raised an aggregate of $7.5 million in warrant exercises and drawdowns on its recently adopted equity line Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” […]